Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas

Takeyama K, Monti S, Manis JP, Dal Cin P, Getz G, Beroukhim R, Dutt S, Aster JC, Alt FW, Golub TR, et al. Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas. Oncogene. 2008;27:318–22.

NOTES

Takeyama, KMonti, SManis, J PDal Cin, PGetz, GBeroukhim, RDutt, SAster, J CAlt, F WGolub, T RShipp, M AengK08 CA122833/CA/NCI NIH HHS/K08 CA122833-01A1/CA/NCI NIH HHS/P01 CA092625/CA/NCI NIH HHS/P01 CA92625/CA/NCI NIH HHS/Research Support, N.I.H., ExtramuralResearch Support, U.S. Gov't, Non-P.H.S.EnglandOncogene. 2008 Jan 10;27(3):318-22. doi: 10.1038/sj.onc.1210650. Epub 2007 Jul 16.

Abstract

p53-Binding protein 1 (53BP1) encodes a critical checkpoint protein that localizes to sites of DNA double-strand breaks (DSBs) and participates in DSB repair. Mice that are 53bp1 deficient or hemizygous have an increased incidence of lymphoid malignancies. However, 53BP1 abnormalities in primary human tumors have not been described. By combining high-density single nucleotide polymorphism (HD SNP) array data and gene expression profiles, we found 9 of 63 newly diagnosed human diffuse large B-cell lymphomas (DLBCLs) with single copy loss of the chromosome 15q15 region including the 53BP1 locus; these nine tumors also had significantly lower levels of 53BP1 transcripts. 53BP1 single copy loss found with the HD SNP array platform was subsequently confirmed by fluorescence in situ hybridization. These studies highlight the role of 53BP1 copy loss in primary human DLBCLs and the value of integrative analyses in detecting this genetic lesion in human tumors.
Last updated on 02/17/2021